OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!

Most cancer drugs don’t actually kill cancer — they just slow it down.In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, reveals why many FDA-approved cancer treatments are cytostatic, meaning they only halt tumor growth — not destroy it. The future, he says, is in cytotoxic precision oncology: treatments designed to actually kill cancer cells while sparing healthy ones.Dr. Prato breaks down the crucial difference between managing and eliminating cancer, and explains why the immune system must be engaged for durable remissions. Using deep mapping tools like DNA, RNA, spatial biology, and immune profiling, Envita customizes therapies that combine precision targeting with immune activation — shifting the goal from “control” to “cure-driven remission.”🎯 What You’ll Learn in This Episode:The real difference between cytostatic and cytotoxic drugsWhy most new cancer drugs are designed to manage, not eliminate, diseaseHow the immune system provides true cytotoxic killing powerWhy immunotherapy (PD-1s, NK cells) needs customizationHow deep mapping (DNA, RNA, spatial biology) reveals better treatment targetsHow Envita achieved up to 35x improved outcomes in late-stage patients*📊 In published outcomes, precision oncology achieved up to 35x better responses and 43x improved quality of life by focusing on cytotoxic, immune-centered treatment algorithms.*(See Outcomes Disclaimer Below)“Managing cancer isn’t enough — it’s time to design care that actually kills it.”Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.________________________________________Outcomes DisclaimerThe results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.You can read the full peer-reviewed study at:https://www.scirp.org/journal/paperinformation?paperid=132493

Patients don’t die of cancer alone — they die from waiting.In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, exposes how the cancer system’s slow approvals, outdated guidelines, and insurance roadblocks cost patients precious time. Care delayed is care denied — and that’s why Dr. Prato and his team built a precision ecosystem to help patients access advanced, individualized care now.Discover how N of one precision oncology eliminates delays by combining next-generation DNA/RNA sequencing, immune profiling, spatial biology, and molecular heat mapping to design treatments unique to every patient.🎯 What You’ll Learn in This Episode:Why prior authorizations and step therapies delay lifesaving careHow “population health” oncology ignores your personal biologyThe truth about drug pipelines designed to manage — not cure — cancerHow precision mapping (DNA, RNA, immune, spatial) speeds effective treatmentWhy waiting on outdated clinical trial models costs livesHow patients see 35x better responses and 43x better quality of life using targeted, personalized care*📊 In Envita’s published data, late-stage cancer patients achieved dramatically improved outcomes through precision-matched treatments — without the long delays of traditional oncology.**(See Outcomes Disclaimer Below)📍 Envita Medical Centers – Scottsdale, AZ🌐 Learn more: https://www.envita.com📞 Speak to a care coordinator: 866-830-4576“Care delayed is care denied. Precision care saves time — and lives.”Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.________________________________________Outcomes DisclaimerThe results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

What if the best prostate cancer treatment doesn’t cut, burn, or destroy your vitality — yet still teaches your immune system to find and fight cancer throughout the body?In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains how precision oncology and interventional radiology are redefining prostate cancer care. Instead of relying on radical surgery or radiation, Envita uses deep DNA/RNA sequencing, immune profiling, and 3D cone-beam imaging to guide minimally invasive, immune-centered procedures.Dr. Prato discusses the risks of standard prostate surgery — including incontinence, erectile dysfunction, and long-term recurrence — and how precision targeting eliminates guesswork by treating the tumor directly and stimulating the immune system for long-term remission.🎯 What You’ll Learn in This Episode:• Why up to 50% of men experience PSA recurrence after prostate surgery• How interventional oncology delivers treatment directly to the tumor site• Why immune-based, precision care improves long-term outcomes• The difference between radical surgery and image-guided microcatheter treatment• How DNA, RNA, and spatial biology testing reveal cancer’s weak points• Why deep mapping prevents recurrence and protects quality of life📍 Envita Medical Centers – Scottsdale, AZ🌐 Learn more: https://www.envita.com📞 Speak to a care coordinator: 866-830-4576“The future of prostate cancer care is precise, personalized, and immune-centered.”Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.________________________________________Outcomes DisclaimerThe results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

What is the best treatment for advanced melanoma — and why do some therapies fail while others succeed?In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, breaks down the future of melanoma care: deep mapping and immune-centered precision oncology. Using DNA, RNA, and spatial biology, Dr. Prato explains how mapping every pathway — not just BRAF mutations — gives doctors a full picture of the tumor’s environment, revealing why PD-1 inhibitors, BRAF/MEK drugs, and other standard therapies work for only a small group of patients.The key to melanoma, he says, lies in natural killer (NK) cells. These immune cells, trained through AAIT (Autologous Adoptive Immunotherapy), can cross the blood-brain barrier and destroy tumor cells without the side effects of high-dose systemic drugs. By combining deep mapping, immune retraining, and microdosed precision therapies, Envita helps patients move from reactionary care to immune-guided treatment.🎯 What You’ll Learn in This Episode:• Why most standard melanoma treatments only help a small percentage of patients• How DNA, RNA, and spatial biology mapping reveal hidden resistance pathways• The difference between TIL therapy and AAIT (Autoglutid Adaptive Immunotherapy)• How NK and dendritic cells are trained using DAMPs to target melanoma cells• Why changing the tumor microenvironment is critical for immune response• How AAIT avoids cytokine storms and side effects seen in other therapies📍 Envita Medical Centers – Scottsdale, AZ🌐 Learn more: https://www.envita.comDisclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.________________________________________Outcomes DisclaimerThe results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

Repurposed drugs can be powerful in cancer care — but only when they’re matched to the right biology.In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains how deep multi-omics testing (DNA, RNA, immune, and spatial biology) reveals whether agents like ivermectin, methylene blue, mebendazole, or fenbendazole actually fit your tumor’s molecular targets.Many “alternative” treatments fail because they’re given blindly. Precision oncology replaces that guesswork by combining repurposed drugs, on-label therapies, and immunotherapy support into one guided plan designed for your unique cancer. Dr. Prato shows how these strategies are used at Envita to enhance drug delivery, minimize toxicity, and strengthen immune response.🎯 What You’ll Learn in This Episode:• Why repurposed drugs can help — but fail without precision targeting• How DNA, RNA, and immune/spatial mapping identify the right off-label options• When microdosing, compounding, or direct tumor delivery may improve results• Why published studies are a starting point — not a one-size-fits-all guide• How combining on-label and off-label medications improves outcomes safely• Why Envita’s precision oncology achieved better responses and fewer side effects📍 Envita Medical Centers – Scottsdale, AZ🌐 Learn more: https://www.envita.com📞 Speak to a care coordinator: 866-830-4576“Repurposed doesn’t mean random — it means targeted, tested, and personalized.”Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.________________________________________Outcomes DisclaimerThe results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493